Health Canada approved Skyrizi for eligible children and teens with plaque psoriasis. The study found skin clearance in both age groups, supporting a wider use of AbbVie's treatment in Canada.
This gives AbbVie a way to reach eligible young patients in Canada. Study results showed skin clearance in children and adolescents, supporting Skyrizi's use. The report names no setback to this expansion.
Follow AbbVie Inc. (ABBV) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for ABBV